Recent advances in the microbiology of respiratory tract infection in cystic fibrosis

British Medical Bulletin

Volumn 89, Issue 1, 2009, Pages 93-110

  Foweraker, Juliet ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Burkholderia cepacia complex; Cystic fibrosis; Haemophilus influenzae; Non tuberculous mycobacteria; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

RNA 16S; ANTIINFECTIVE AGENT;

ACHROMOBACTER XYLOSOXIDANS; ADAPTATION; ANTIBIOTIC SENSITIVITY; ASPERGILLUS FUMIGATUS; BACTERIAL STRAIN; BIOFILM; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA PSEUDOMALLEI; CANDIDA; CYSTIC FIBROSIS; GENETIC ANALYSIS; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION; MORBIDITY; MORTALITY; MOUTH FLORA; PANDORAEA APISTA; PATHOGENICITY; PATIENT CARE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; RESPIRATORY TRACT INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SCEDOSPORIUM APIOSPERMUM; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UPPER RESPIRATORY TRACT; VIRAL RESPIRATORY TRACT INFECTION; BACTERIAL INFECTION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 68649127406     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldn050     Document Type: Review

References (66)

1. Burns JL, Emerson J, Stapp JR et al. (1998) Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis, 27, 158-163
2. Govan JR, Nelson JW (1992) Microbiology of lung infection in cystic fibrosis. Br Med Bull, 48, 912-930
3. Hart CA, Winstanley C (2002) Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br Med Bull, 61, 81-96
4. Antibiotic Treatment for Cystic Fibrosis (2002) Report of the UK Cystic Fibrosis Trust's Antibiotic Group, 2nd ed. Cystic Fibrosis Trust
5. Davies JC (2006) Current and novel antimicrobial approaches. Prog Respir Res, 34, 180-186
6. Armstrong DS, Grimwood K, Carzino R et al. (1995) Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ, 310, 1571-1572
7. Kahl BC, Duebbers A, Lubritz G et al. (2003) Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol, 41, 4424-4427
8. Smyth A, Walters S (2003) Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev: CD001912
9. Goerke C, Matias y Papenberg S, Dasbach S et al. (2004) Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J Infect Dis, 189, 724-734
10. Prunier AL, Malbruny B, Laurans M et al. (2003) High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis, 187, 1709-1716
11. Coia JE, Duckworth GJ, Edwards DI et al. (2006) Guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect, 63 (Suppl 1), S1-S44
12. Vergison A, Denis O, Deplano A et al. (2007) National survey of molecular epidemiology of Staphylococcus aureus colonization in Belgian cystic fibrosis patients. J Antimicrob Chemother, 59, 893-899
13. Macfarlane M, Leavy A, McCaughan J et al. (2007) Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect, 65, 231-236
14. Roman F, Canton R, Perez-Vazquez M et al. (2004) Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol, 42, 1450-1459
15. Watson ME Jr., Burns JL, Smith AL (2004) Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology, 150, 2947-2958
16. Starner TD, Shrout JD, Parsek MR et al. (2008) Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. Antimicrob Agents Chemother, 52, 137-145
17. del Campo R, Morosini MI, de la Pedrosa EG et al. (2005) Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. J Clin Microbiol, 43, 2207-2214
18. Garcia-Castillo M, Morosini MI, Valverde A et al. (2007) Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. J Antimicrob Chemother, 59, 301-314
19. Southern KW, Barker PM, Solis A (2004) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev: CD002203
20. Al-Aloul M, Crawley J, Winstanley C et al. (2004) Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax, 59, 334-336
21. Jones AM, Govan JR, Doherty CJ et al. (2001) Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet, 358, 557-558
22. Fothergill JL, Panagea S, Hart CA et al. (2007) Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain. BMC Microbiol, 7, 45
23. Juhas M, Eberl L, Tummler B (2005) Quorum sensing: the power of cooperation in the world of Pseudomonas. Environ Microbiol, 7, 459-471
24. Haussler S, Ziegler I, Lottel A et al. (2003) Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol, 52, 295-301
25. Foweraker JE, Laughton CR, Brown DF et al. (2005) Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother, 55, 921-927
26. Perry JD, Laine L, Hughes S et al. (2008) Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother, 61, 1057-1061
27. Smith AL, Fiel SB, Mayer-Hamblett N et al. (2003) Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest, 123, 1495-1502
28. Govan JR, Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev, 60, 539-574
29. Pitt TL, Sparrow M, Warner M et al. (2003) Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax, 58, 794-796
30. Cappelletty DM, Rybak MJ (1996) Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 40, 677-683
31. Aaron SD, Vandemheen KL, Ferris W et al. (2005) Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet, 366, 463-471
32. Oliver A, Canton R, Campo P et al. (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science, 288, 1251-1254
33. Macia MD, Blanquer D, Togores B et al. (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother, 49, 3382-3386
34. Kenna D, Doherty CJ, Foweraker J et al. (2007) Pseudomonas aeruginosa hypermutators in cystic fibrosis. Microbiology, 153, 1852-1859
35. Stewart PS, Franklin MJ (2008) Physiological heterogeneity in biofilms. Nat Rev Microbiol, 6, 199-210
36. Moskowitz SM, Foster JM, Emerson J et al. (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol, 42, 1915-1922
37. Smith EE, Buckley DG, Wu Z et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A, 103, 8487-8492
38. Mena A, Smith EE, Burns JL et al. (2008) Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol, 190, 7910-7917
39. Vandamme P, Holmes B, Vancanneyt M et al. (1997) Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol, 47, 1188-1200
40. Vanlaere E, Lipuma JJ, Baldwin A et al. (2008) Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol, 58, 1580-1590
41. Mahenthiralingam E, Urban TA, Goldberg JB (2005) The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol, 3, 144-156 (Pubitemid 40207595)
42. Govan JR, Brown AR, Jones AM (2007) Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol, 2, 153-164
43. Kalish LA, Waltz DA, Dovey M et al. (2006) Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med, 173, 421-425
44. St Denis M, Ramotar K, Vandemheen K et al. (2007) Infection with Burkholderia cepacia complex bacteria and pulmonary exacerbations of cystic fibrosis. Chest, 131, 1188-1196
45. Holland DJ, Wesley A, Drinkovic D et al. (2002) Cystic fibrosis and Burkholderia pseudo-mallei infection: an emerging problem? Clin Infect Dis, 35, e138-e140
46. Goss CH, Mayer-Hamblett N, Aitken ML et al. (2004) Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax, 59, 955-959
47. De Baets F, Schelstraete P, Van Daele S et al. (2007) Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros, 6, 75-78
48. Jorgensen IM, Johansen HK, Frederiksen B et al. (2003) Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol, 36, 439-446
49. Coenye T, Goris J, Spilker T et al. (2002) Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol, 40, 2062-2069
50. Wellinghausen N, Kothe J, Wirths B et al. (2005) Superiority of molecular techniques for identification of gram-negative, oxidase-positive rods, including morphologically nontypical Pseudomonas aeruginosa, from patients with cystic fibrosis. J Clin Microbiol, 43, 4070-4075
51. Jordan PW, Stanley T, Donnelly FM et al. (2007) Atypical mycobacterial infection in patients with cystic fibrosis: update on clinical microbiology methods. Lett Appl Microbiol, 44, 459-466
52. Olivier KN, Weber DJ, Wallace RJ Jr. et al. (2003) Nontuberculous mycobacteria. I: multi-center prevalence study in cystic fibrosis. Am J Respir Crit Care Med, 167, 828-834
53. Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I et al. (2005) Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol, 43, 3467-3470
54. Catherinot E, Clarissou J, Etienne G et al. (2007) Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun, 75, 1055-1058
55. Howard ST, Rhoades E, Recht J et al. (2006) Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of gly-copeptidolipid and reacquisition of an invasive phenotype. Microbiology, 152, 1581-1590
56. Greendyke R, Byrd TF (2008) Differential antibiotic susceptibility of Mycobacterium absces-sus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother, 52, 2019-2026
57. Griffith DE, Aksamit T, Brown-Elliott BA et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 175, 367-416
58. Stevens DA, Moss RB, Kurup VP et al. (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis, 37 (Suppl 3), S225-S264
59. Shoseyov D, Brownlee KG, Conway SP et al. (2006) Aspergillus bronchitis in cystic fibrosis. Chest, 130, 222-226
60. Cimon B, Carrere J, Vinatier JF et al. (2000) Clinical significance of Scedosporium apiosper-mum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis, 19, 53-56
61. Duan K, Dammel C, Stein J et al. (2003) Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol, 50, 1477-1491
62. Tunney MM, Field TR, Moriarty TF et al. (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med, 177, 995-1001
63. Rogers GB, Carroll MP, Serisier DJ et al. (2004) Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol, 42, 5176-5183
64. Wat D (2003) Impact of respiratory viral infections on cystic fibrosis. Postgrad Med J, 79, 201-203 (Pubitemid 36605781)
65. Wedzicha JA, Seemungal TA (2007) COPD exacerbations: defining their cause and prevention. Lancet, 370, 786-796
66. Kistler A, Avila PC, Rouskin S et al. (2007) Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhino-virus diversity. J Infect Dis, 196, 817-825